Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 1 , Pages 115-118 , January 2006

Pharmacological Management of Preschool ADHD

,Accepted 26 August 2005.

REFERENCES 

  1. Bolanos CA , Barrot M , Berton O , Wallace-Balck D , Nestler EJ . Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood . Biol Psychiatry . 2003;54:1317–1329
  2. Brandon CL , Steiner J . Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum . Eur J Neurosci . 2003;18:1584–1592
  3. Carter AS , Briggs-Gowan MJ , Davis NO . Assessment of young children's social-emotional development and psychopathology: recent advances and recommendations for practice . J Child Psychol Psychiatry . 2004;45:109–134
  4. Conners C , Sitarenios G , Parker J , Epstein J . The Revised Conners Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity . J Abnorm Child Psychol . 1998;26:257–268
  5. In:  DelCarmen-Wiggins R ,  Carter A editor. Handbook of Infant, Toddler, and Preschool Mental Health Assessment . New York: Oxford University Press; 2004;
  6. Greenhill LL, Abikoff H, Chuang S et al. (in press), Efficacy and safety of immediate-release methylphenidate in the treatment of preschool children with ADHD. J Am Acad Child Adolesc Psychiatry
  7. Hayes SC , Barlow DH , Nelson-Gray RO . The Scientist Practitioner . 2nd ed.. Boston: Allyn & Bacon; 1999;
  8. Sackett DL , Straus SE , Richardson WS , Rosenberg W , Haynes RB . Evidence-based Medicine: How to Practice and Teach EBM . 2nd ed.. New York: Churchill Livingstone; 2000;
  9. Zito JM , Safer DJ , dos Reis S , Gardner JF , Boles M , Lynch F . Trends in the prescribing of psychotropic medications to preschoolers . JAMA . 2000;283:1025–1030

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration (FDA). We fully appreciate that for virtually all disorders medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. The responses from the expert clinicians are not meant to be practice guidelines but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. Kratochvil has received grant support from, is a consultant to, and/or member of the speaker's bureau of Eli Lilly, GlaxoSmithKline, Forest, Shire, Cephalon, Novartis, McNeil, Organon, AstraZeneca, Pfizer. Dr. Egger has grant support from Pfizer. Dr. Greenhill has received grant support from, is a consultant to, and/or a member of the speaker's bureau of Wyeth Ayerst, Glaxo Wellcome, Eli Lilly, Alza, Shire, Medeva, Cephalon, Noven, Somerset, McNeil, Celltech, Novartis, Solvay, Sanofi Aventis, Otsuka. Dr. McGough has received support from Eli Lilly (grant/research support, consulting fees, speaker's bureau), McNeil (grant/research support, consulting fees, speaker's bureau), Novartis (grant/research support, consulting fees, speaker's bureau), Shire (grant/research support, consulting fees, speaker's bureau), Pfizer (grant/research support, consulting fees), and New River Pharmaceuticals (grant/research support).

PII: S0890-8567(09)62268-1

doi: 10.1097/01.chi.0000186451.49579.0a

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 1 , Pages 115-118 , January 2006

Article Tools